Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties
| Autor: | Timothy J. Burns, Sheldon W. May, Amna Ali, G.R. Green, Diane F. Matesic, Jacob Lucrezi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Models
Molecular Stereochemistry Antineoplastic Agents Hydroxamic Acids Histone Deacetylases Cell Line Fatty Acids Monounsaturated Cell Line Tumor parasitic diseases medicine Animals Humans Pharmacology (medical) Vorinostat Caproates Pharmacology chemistry.chemical_classification Monooxygenase In vitro Rats Histone Deacetylase Inhibitors Enzyme Oncology chemistry Biochemistry Cell culture Acetylation Histone deacetylase Peptidylglycine alpha-amidating monooxygenase medicine.drug |
| Zdroj: | Investigational new drugs. 33(4) |
| ISSN: | 1573-0646 |
| Popis: | 4-Phenyl-3-butenoic acid (PBA) is an inhibitor of peptidylglycine alpha-amidating monooxygenase with anti-inflammatory properties that has been shown to inhibit the growth of ras-mutated epithelial and human lung carcinoma cells. In this report, we show that PBA also increases the acetylation levels of selected histone subtypes in a dose and time dependent manner, an effect that is attributable to the inhibition of histone deacetylase (HDAC) enzymes. Comparison studies with the known HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) using high resolution two-dimensional polyacrylamide gels and Western analysis provide evidence that PBA acts as an HDAC inhibitor within cells. PBA and a more potent amidation inhibitor, 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester (AOPHA-Me), inhibit HDAC enzymes in vitro at micromolar concentrations, with IC50 values approximately 30 fold lower for AOPHA-Me than PBA for selected HDAC isoforms. Overall, these results indicate that PBA and AOPHA-Me are novel anti-tumorigenic HDAC inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink